Abstract 513P
Background
Oligodendrogliomas (OLIG), are rare tumors of the central nervous system. The current WHO classification requires the presence of IDH mutation and 1p/19q codeletion. Grade 3 OLIG presents a higher number of chromosomal alterations than grade 2, indicating that progression to malignancy is associated with the acquisition of multiple genetic abnormalities. An increased incidence of deletions in the short arm of chromosome 9 has been found. CDKN2A is located on chromosome 9 and encodes for 2 proteins p16 (or p16INK4a) and p14arf. Previous studies have found CDKN2A involvement at 9p21 with homozygous deletion in 25% of grade 3 oligodendrogliomas. Many of these studies were performed in a series of patients with OLIG diagnosed by histopathological criteria, but not by current molecular criteria. This study analyzed the cyclin pathway in a series of oligodendrogliomas with IDH mutation and 1p/19q codeletion.
Methods
Cases with a morphological diagnosis of oligodendroglioma were identified (182 cases). This same cohort was subsequently reclassified according to current WHO criteria (91 cases). The median follow-up of this case series was 9 years. In the reclassified cohort, p16, pRb and D1 cyclin were studied by immunohistochemistry.
Results
There was no p16 expression in 16 of 71 cases (22.5%). The absence of expression was significantly associated with a worse prognosis. Median OS in the absence of p16 of 9 years (95%IC 9.36-17.35) vs 13.35 years when there was p16 expression (95%IC 9.36-17.35) p=0.023 HR 0.41. In grade 2 oligodendrogliomas, the median OS was 10.86 vs 13.35 p=0.754, and in grade 3, 4.76 vs 17.49 p=0.010. According to a multivariate analysis including data on the extent of surgery, tumor grade, adjuvant treatment, and p16, only the absence of p16 showed a statistically significant prognostic value (p=0.034). There was no correlation between the loss of p16 and the presence of microvascular proliferation, necrosis, or uptake on MRI. In grade 2 oligodendrogliomas, high cyclin D1 expression was associated with worse survival; 12.3 vs 0.78 years (p=0.001).
Conclusions
Loss of p16 is more frequent in grade 3 than in grade 2 oligodendrogliomas and is associated with worse survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.A. Vaz Salgado: Financial Interests, Personal, Advisory Board: Novocure; Financial Interests, Personal and Institutional, Coordinating PI: Pfizer. J.M. Sepulveda Sanchez: Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Personal, Advisory Board: MSD, Novocure, CeCaVa, Cantex; Financial Interests, Personal and Institutional, Research Grant: Pfizer, Cantex. A. Carrato Mena: Financial Interests, Personal and Institutional, Advisory Board: Pfizer, Bayer, Merck, MSD, Novartis, Shire. L.L. Ley: Non-Financial Interests, Member, President: Sociedad Española de Neurocirugía; Non-Financial Interests, Member: Grupo Español de Investigaciones Neurooncológicas. All other authors have declared no conflicts of interest.
Resources from the same session
56P - SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Presenter: Christa Dijkhuizen
Session: Poster session 09
57P - Metastasis organotropism: Unveiling associated proteins using network biology
Presenter: Margarida Carrolo
Session: Poster session 09
59P - Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Presenter: Chaiyapong Ngamchokwathana
Session: Poster session 09
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Presenter: Xuejin Ou
Session: Poster session 09
61P - Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Presenter: Amit Badola
Session: Poster session 09
62P - Prebiotics modulate gut microbiota-mediated T cell immunity to enhance sintilimab inhibition of lung cancer
Presenter: QIN YAN
Session: Poster session 09
63P - Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Presenter: Andrei Cismaru
Session: Poster session 09
64P - Developing novel therapeutics for bladder cancer leveraging drosophila models
Presenter: Takuya Moriguchi
Session: Poster session 09
65P - Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB-CTCF-p16 pathway
Presenter: xuefeng zheng
Session: Poster session 09
66P - Exploring the radiobiology and dosimetry of targeted alpha therapy as a tool to optimize its clinical application: A preclinical study
Presenter: Maria Filomena Botelho
Session: Poster session 09